



Finch Announces Resignation of Chief Financial Officer

January 2, 2025

Boston, MA, January 2, 2025 -- On January 2, 2025, Finch Therapeutics Group, Inc. (the "Company") announced that Lance Thibault, the Company's Chief Financial Officer, had resigned effective as of the close of business on December 31, 2024. Mr. Thibault had provided consulting services to the Company, including in his capacity as Chief Financial Officer, pursuant to an agreement between the Company and Mr. Thibault's employer, Danforth Advisors LLC, since May 2023. The Company currently expects that Danforth Advisors LLC will continue to assist the Company with the preparation of its financial statements and maintenance of its books and records

About Finch

Finch Therapeutics is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch's objectives are to realize the value of its intellectual property estate through licensing its technology to collaboration partners and enforcing its patent rights against infringing parties through intellectual property litigation and, in certain cases, to generate additional data on selected product candidates through academic collaborations.

For investor inquiries, please contact:

IR@finchtherapeutics.com

For media inquiries, please contact:

info@finchtherapeutics.com